Premium
Lung cavitation due to Mycobacterium xenopi in a renal transplant recipient
Author(s) -
MartínPenagos L.,
Rodrigo E.,
Ruíz J.C.,
Agüero J.,
FernandezMazarrasa C.,
Martínez L.,
Piñera C.,
Arias M.
Publication year - 2009
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/j.1399-3062.2009.00376.x
Subject(s) - medicine , immunosuppression , pyrazinamide , sputum , sirolimus , levofloxacin , regimen , lung , rifampicin , azithromycin , microbiology and biotechnology , antibiotics , tuberculosis , pathology , biology
Mycobacterium xenopi is an unusual pathogen and few such cases have been reported in the literature. We report the case of a patient with a sirolimus‐based immunosuppressive regimen, who developed lung cavitation. M. xenopi was isolated from the sputum. The patient was treated initially with rifampicin, isoniazid, and pyrazinamide; levofloxacin was added to the treatment regimen after M. xenopi was demonstrated. A possible relationship between sirolimus and M. xenopi infection has been postulated, probably due to the combination of pulmonary toxicity and cellular immunosuppression of rapamycin.